DE68904459T2 - Antacidzusammensetzungen mit laengerer verweilzeit im magen. - Google Patents
Antacidzusammensetzungen mit laengerer verweilzeit im magen.Info
- Publication number
- DE68904459T2 DE68904459T2 DE8989304013T DE68904459T DE68904459T2 DE 68904459 T2 DE68904459 T2 DE 68904459T2 DE 8989304013 T DE8989304013 T DE 8989304013T DE 68904459 T DE68904459 T DE 68904459T DE 68904459 T2 DE68904459 T2 DE 68904459T2
- Authority
- DE
- Germany
- Prior art keywords
- preparation according
- antacid
- weight
- emulsion
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940069428 antacid Drugs 0.000 title claims abstract description 34
- 239000003159 antacid agent Substances 0.000 title claims abstract description 34
- 230000001458 anti-acid effect Effects 0.000 title claims abstract description 34
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims description 16
- 210000002784 stomach Anatomy 0.000 title description 13
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 18
- 239000007787 solid Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920000098 polyolefin Polymers 0.000 claims abstract description 9
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 239000008117 stearic acid Substances 0.000 claims abstract description 4
- 239000012875 nonionic emulsifier Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 17
- -1 12-hydroxystearic acid ester Chemical class 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims description 7
- 229960001545 hydrotalcite Drugs 0.000 claims description 7
- 229910001701 hydrotalcite Inorganic materials 0.000 claims description 7
- 229960004612 almagate Drugs 0.000 claims description 6
- MTEOMEWVDVPTNN-UHFFFAOYSA-E almagate Chemical compound O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Al+3].[O-]C([O-])=O MTEOMEWVDVPTNN-UHFFFAOYSA-E 0.000 claims description 6
- JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 claims description 6
- 229960004018 magaldrate Drugs 0.000 claims description 6
- 239000008385 outer phase Substances 0.000 claims description 6
- 239000007910 chewable tablet Substances 0.000 claims description 5
- 239000008384 inner phase Substances 0.000 claims description 5
- ULQISTXYYBZJSJ-UHFFFAOYSA-N R-12-HOA Natural products CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940114072 12-hydroxystearic acid Drugs 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 230000027119 gastric acid secretion Effects 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 2
- 229960000620 ranitidine Drugs 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002888 oleic acid derivatives Chemical class 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000005691 triesters Chemical class 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 abstract description 9
- 230000002035 prolonged effect Effects 0.000 abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000001593 sorbitan monooleate Substances 0.000 description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 description 4
- 229940035049 sorbitan monooleate Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000001711 oxyntic cell Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888809421A GB8809421D0 (en) | 1988-04-21 | 1988-04-21 | Antacid compositions with prolonged gastric residence time |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68904459D1 DE68904459D1 (de) | 1993-03-04 |
| DE68904459T2 true DE68904459T2 (de) | 1993-05-13 |
Family
ID=10635574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8989304013T Expired - Fee Related DE68904459T2 (de) | 1988-04-21 | 1989-04-21 | Antacidzusammensetzungen mit laengerer verweilzeit im magen. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5288506A (ja) |
| EP (1) | EP0338861B1 (ja) |
| JP (1) | JPH0764724B2 (ja) |
| KR (1) | KR950007205B1 (ja) |
| AT (1) | ATE84708T1 (ja) |
| AU (1) | AU616257B2 (ja) |
| CA (1) | CA1336495C (ja) |
| DE (1) | DE68904459T2 (ja) |
| DK (1) | DK188489A (ja) |
| ES (1) | ES2044099T3 (ja) |
| FI (1) | FI98886C (ja) |
| GB (1) | GB8809421D0 (ja) |
| GR (1) | GR3006908T3 (ja) |
| HU (1) | HU211236A9 (ja) |
| IE (1) | IE61866B1 (ja) |
| NO (1) | NO176868C (ja) |
| NZ (1) | NZ228836A (ja) |
| PT (1) | PT90328B (ja) |
| ZA (1) | ZA892920B (ja) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0578732B1 (en) * | 1991-04-04 | 1996-06-19 | The Procter & Gamble Company | Chewable antacid compositions |
| FR2677546B1 (fr) * | 1991-06-12 | 1994-01-21 | Fabienne Joanny | Composition therapeutique pour liberation prolonge de magnesium. |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| US5622980A (en) * | 1993-08-17 | 1997-04-22 | Applied Analytical Industries, Inc. | Oral compositions of H2-antagonists |
| DE4415999A1 (de) * | 1994-05-06 | 1995-11-09 | Bolder Arzneimittel Gmbh | Magensäurebindende Kaupastillen |
| AU2576295A (en) * | 1994-06-06 | 1996-01-04 | Yamanouchi Pharmaceutical Co., Ltd. | Solid antacid and process for producing the same |
| US6306828B1 (en) * | 1995-04-06 | 2001-10-23 | Baxter International, Inc. | Enantiomerically-enhanced nutritional energy substrates |
| EP0867191A4 (en) * | 1995-11-27 | 2000-01-05 | Yamanouchi Pharma Co Ltd | MEDICINE COMPOSITION |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| FR2793688B1 (fr) * | 1999-05-21 | 2003-06-13 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
| ATE297433T1 (de) | 1999-07-22 | 2005-06-15 | Warner Lambert Co | Filmbildende zusammensetzungen aus pullulan |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6780880B1 (en) * | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| EP1245227A1 (en) * | 2001-03-31 | 2002-10-02 | Jagotec Ag | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
| SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
| CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
| SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| EP1603537A4 (en) * | 2003-02-20 | 2009-11-04 | Santarus Inc | IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2004257864A1 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| JP2006528181A (ja) * | 2003-07-18 | 2006-12-14 | サンタラス インコーポレイティッド | 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法 |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| JP2006131581A (ja) * | 2004-11-09 | 2006-05-25 | Kyowa Chem Ind Co Ltd | 崩壊剤及びこれを含有する崩壊性成形物 |
| EP2026768B1 (en) * | 2006-06-01 | 2018-02-28 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| RS54024B1 (en) | 2012-10-12 | 2015-10-30 | Omya International Ag | GASTRORETENCY FORMULATION OF MEDICINES AND SYSTEMS FOR DELIVERY AND METHODS OF THEIR PREPARATION USING FUNCTIONALIZED CALCIUM CARBONATE |
| EP3034070A1 (en) | 2014-12-18 | 2016-06-22 | Omya International AG | Method for the production of a pharmaceutical delivery system |
| EP3069713A1 (en) | 2015-03-20 | 2016-09-21 | Omya International AG | Dispersible dosage form |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CA2898600A1 (en) * | 2015-07-28 | 2017-01-28 | Jayson King | Stuffing box containment apparatus |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| EP3269361A1 (en) | 2016-07-14 | 2018-01-17 | Omya International AG | Dosage form |
| CN110327370B (zh) * | 2019-04-16 | 2021-02-23 | 马德君 | 阴离子黏土用于制备驱铅药物的用途 |
| CN110780063A (zh) * | 2019-12-10 | 2020-02-11 | 无锡市尚沃医疗电子股份有限公司 | 一种呼气氨检测方法和装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1416304A (fr) * | 1961-10-10 | 1965-11-05 | Smith Kline French Lab | Perfectionnements apportés aux tablettes et comprimés renfermant une importante quantité d'ingrédient actif libéré pendant un laps de temps prolongé, et aux procédés pour leur préparation |
| CA948107A (en) * | 1970-04-28 | 1974-05-28 | Robert S. Joslin | Coated antacid compositions of improved taste |
| US4101650A (en) * | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
| HU179474B (en) * | 1978-02-24 | 1982-10-28 | Laszlo Gyarmati | Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material |
| MTP930B (en) * | 1982-04-30 | 1984-04-10 | Delandale Labs Ltd | Substained release lithium-containing tablets and method for their manufacture |
| US4605551A (en) * | 1984-11-30 | 1986-08-12 | William H. Rorer, Inc. | Dry oil coated antacid process |
| US4778676A (en) * | 1985-12-20 | 1988-10-18 | Warner-Lambert Company | Confectionery delivery system for actives |
| JPS62195323A (ja) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
| GB2201594B (en) * | 1986-06-24 | 1991-02-13 | Istvan Racz | Production of acid binding pharmaceutical preparations |
-
1988
- 1988-04-21 GB GB888809421A patent/GB8809421D0/en active Pending
-
1989
- 1989-04-19 AU AU33175/89A patent/AU616257B2/en not_active Ceased
- 1989-04-19 DK DK188489A patent/DK188489A/da not_active Application Discontinuation
- 1989-04-20 PT PT90328A patent/PT90328B/pt not_active IP Right Cessation
- 1989-04-20 NZ NZ228836A patent/NZ228836A/xx unknown
- 1989-04-20 ZA ZA892920A patent/ZA892920B/xx unknown
- 1989-04-20 NO NO891641A patent/NO176868C/no unknown
- 1989-04-20 IE IE128289A patent/IE61866B1/en not_active IP Right Cessation
- 1989-04-20 US US07/340,780 patent/US5288506A/en not_active Expired - Fee Related
- 1989-04-20 FI FI891896A patent/FI98886C/fi not_active IP Right Cessation
- 1989-04-20 KR KR1019890005207A patent/KR950007205B1/ko not_active IP Right Cessation
- 1989-04-21 AT AT89304013T patent/ATE84708T1/de not_active IP Right Cessation
- 1989-04-21 CA CA000597383A patent/CA1336495C/en not_active Expired - Fee Related
- 1989-04-21 DE DE8989304013T patent/DE68904459T2/de not_active Expired - Fee Related
- 1989-04-21 EP EP89304013A patent/EP0338861B1/en not_active Expired - Lifetime
- 1989-04-21 JP JP1100327A patent/JPH0764724B2/ja not_active Expired - Lifetime
- 1989-04-21 ES ES89304013T patent/ES2044099T3/es not_active Expired - Lifetime
-
1993
- 1993-01-28 GR GR930400155T patent/GR3006908T3/el unknown
-
1995
- 1995-06-30 HU HU95P/P00697P patent/HU211236A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3317589A (en) | 1989-10-26 |
| CA1336495C (en) | 1995-08-01 |
| NO176868C (no) | 1995-06-14 |
| FI98886B (fi) | 1997-05-30 |
| US5288506A (en) | 1994-02-22 |
| JPH0764724B2 (ja) | 1995-07-12 |
| ATE84708T1 (de) | 1993-02-15 |
| GR3006908T3 (ja) | 1993-06-30 |
| DK188489A (da) | 1989-10-23 |
| GB8809421D0 (en) | 1988-05-25 |
| DK188489D0 (da) | 1989-04-19 |
| PT90328B (pt) | 1994-11-30 |
| IE891282L (en) | 1989-10-21 |
| PT90328A (pt) | 1989-11-10 |
| EP0338861A2 (en) | 1989-10-25 |
| NZ228836A (en) | 1990-09-26 |
| FI98886C (fi) | 1997-09-10 |
| IE61866B1 (en) | 1994-11-30 |
| FI891896A0 (fi) | 1989-04-20 |
| KR890015733A (ko) | 1989-11-25 |
| EP0338861A3 (en) | 1990-09-19 |
| EP0338861B1 (en) | 1993-01-20 |
| ES2044099T3 (es) | 1994-01-01 |
| AU616257B2 (en) | 1991-10-24 |
| HU211236A9 (en) | 1995-11-28 |
| DE68904459D1 (de) | 1993-03-04 |
| NO176868B (no) | 1995-03-06 |
| NO891641L (no) | 1989-10-23 |
| JPH0215025A (ja) | 1990-01-18 |
| ZA892920B (en) | 1989-12-27 |
| FI891896A (fi) | 1989-10-22 |
| KR950007205B1 (ko) | 1995-07-04 |
| NO891641D0 (no) | 1989-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68904459T2 (de) | Antacidzusammensetzungen mit laengerer verweilzeit im magen. | |
| EP0068191B1 (de) | Orale Dipyridamolformen | |
| DE3884461T2 (de) | Antibiotikum-Polymer Zusammensetzung. | |
| AT398165B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung | |
| EP0108898B1 (de) | Neue orale Mopidamolformen | |
| DE69319320T2 (de) | Arzneimittelzubereitung mit verspätet einsetzender kontinuierlicher Freisetzung | |
| DE69514192T2 (de) | Arzneimittel und/oder Nahrungsmikrokapseln zur oralen Verabreichung | |
| DE69205971T2 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
| DE69022876T2 (de) | Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. | |
| DE3780222T2 (de) | Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung. | |
| DE3879286T2 (de) | Fluessige dispersion zur oralen verabreichung. | |
| DE3872199T2 (de) | Pharmazeutische zusammensetzungen. | |
| DE2907215A1 (de) | Feste depotarzneimittelpraeparate und verfahren zu deren herstellung | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| CH640738A5 (de) | Arzneimitteltablette zur peroralen applikation und verfahren zu deren herstellung. | |
| CH630257A5 (en) | Sustained release formulation | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE69521924T2 (de) | Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid | |
| DE69619052T2 (de) | Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung | |
| EP1509207B1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| EP0722719B1 (de) | Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen | |
| CH674148A5 (ja) | ||
| DE1492253A1 (de) | Verfahren zur Herstellung von Tabletten mit protrahierter Wirkung | |
| DE3419128A1 (de) | Dihydropyridinpraeparate und verfahren zu ihrer herstellung | |
| DE3419131A1 (de) | Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: FORDONAL S.L., MADRID, ES |
|
| 8339 | Ceased/non-payment of the annual fee |